Datroway (Datopotamab Deruxtecan-Dlnk) for Breast Cancer

Overview
Datroway is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with unresectable (not viable for surgery) or metastatic (advanced), hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. To be eligible, a person must have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. Datroway is also known by its drug name, datopotamab deruxtecan-dlnk.

Datroway is a Trop-2-directed antibody and topoisomerase inhibitor conjugate. It works by targeting Trop-2, a protein commonly found on breast cancer cells, and delivering a cancer-fighting drug directly to these cells, which helps slow or stop the progression of the disease.

How do I take it?
Prescribing information states that Datroway is given as an intravenous (IV) infusion. The recommended dosing schedule is one infusion every three weeks (21-day cycle) until the disease progresses or unacceptable side effects occur. Recipients are premedicated to prevent infusion reactions, nausea, and vomiting. It is important that Datroway is administered as prescribed by a health care provider.

Side effects
Common side effects of Datroway include stomatitis (inflammation in the mouth), nausea, fatigue, decreased white blood cells, decreased calcium levels, alopecia (hair loss), decreased hemoglobin, constipation, decreased neutrophils, dry eye, vomiting, and increased levels of liver enzymes such as ALT, AST, and alkaline phosphatase.

Rare but serious side effects may include interstitial lung disease (a lung condition that causes inflammation or scarring), severe eye problems like keratitis (inflammation of the cornea) or blepharitis (inflammation of the eyelids), and severe oral mucositis (mouth sores). Datroway can also harm a developing fetus, so effective contraception is recommended during treatment.

For more information about this treatment, visit:

Datroway (Datopotamab Deruxtecan-Dlnk) Injection, for Injection, for Intravenous Use — Daiichi Sankyo